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TransglucosylationCholesteryl glucoside (b-ChlGlc), a monoglucosylated derivative of cholesterol, is involved in the regula-
tion of heat shock responses. b-ChlGlc, which is rapidly induced in response to heat shock, activates heat
shock transcription factor 1 (HSF1) leading to the expression of heat shock protein 70 (HSP70) in human
ﬁbroblasts. Identiﬁcation and biochemical characterization of the enzyme responsible for b-ChlGlc
formation is important for a complete understanding of the molecular mechanisms leading to HSP70-
induction following heat shock. Recently, we demonstrated that b-ChlGlc synthesis is not dependent
on UDP-Glucose but glucosylceramide (GlcCer) in animal tissue and human ﬁbroblasts. In this study,
we examined the possibility of glucocerebrosidase, a GlcCer-degrading glycosidase, acting as b-ChlGlc-
synthesizing enzyme. Overexpression of b-glucosidase 1 (GBA1, lysosomal acid b-glucocerebrosidase)
led to an increase in cholesterol glucosylation activity in human ﬁbroblasts. Using a cell line generated
from type 2 Gaucher disease patients with severe defects in GBA1 activity, we found that cholesterol glu-
cosylation activity was very low in the cells and the overexpression of GBA1 rescued the activity. In addi-
tion, puriﬁed recombinant GBA1 exhibits conduritol B-epoxide-sensitive cholesterol glucosylation
activity. The optimum pH and temperature for cholesterol glucosylation by GBA1 were at about 5.3
and 43 C, respectively. Short chain C8:0-GlcCer was the most effective donor for cholesterol glucosyla-
tion activity among GlcCer containing saturated fatty acid (C8:0 to C18:0) tested. GlcCer containing
mono-unsaturated fatty acid was more preferred substrate for cholesterol glucosylation when compared
with GlcCer containing same chain length of saturated fatty acid. These results demonstrate, for the ﬁrst
time, a novel function of GBA1 as a b-ChlGlc-synthesizing enzyme. Therefore, our results also reveal a
new pathway for glycolipid metabolism in mammals.
 2013 Elsevier Inc. Open access under CC BY-NC-ND license. 1. Introduction
Steryl glucoside (SG) is the most abundant membrane-bound
sterol derivative found in many organisms [1]. Previously, we
reported that heat shock rapidly induces SG in mold cells [2],
human fetal lung ﬁbroblast cells (TIG-3) [3], and rat gastric mucosa
[4]. Cholesteryl glucoside (1-O-cholesteryl-b-D-glucopyranoside,
b-ChlGlc), a glucosylated derivative of cholesterol, is a member ofSG family. Heat shock causes rapid accumulation of b-ChlGlc in
cells, followed by HSF1 activation and HSP70 induction [4,5]. We
have previously reported that the addition of exogenous b-ChlGlc
induces HSF1 activation and HSP70 induction in human ﬁbroblasts
[5]. Thus, b-ChlGlc may serve as a heat-sensing signal molecule
that is required for HSP70 gene activation. However, the precise
functions of b-ChlGlc remain unclear.
The formation of SG is known to be catalyzed by a membrane-
bound enzyme, namely UDP-glucose:sterol glucosyltransferase
(UDPG-SGTase, EC 2.4.1.173), and UDPG-SGTases from a number
of organisms have been cloned [1]. Additionally, UDPG-SGTase
expressed in a slime mold, Physarum polycephalum, has been char-
acterized [6,7]. However, a sterol glucosyltransferase (SGTase) has
not yet been identiﬁed in animals. Therefore, in order to under-
stand the molecular mechanisms leading to HSP70-induction in
animals, it is essential to identify the SGTase responsible for the
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for SGTase using ﬂuorescence-labeled cholesterol (25-NBD-Choles-
terol). Using this assay, we demonstrated that SGTase of animal
origin is a novel enzyme, since glucosylceramide (GlcCer), not
UDP-glucose, functioned as a glucose donor for b-ChlGlc formation
[8]. Supporting this we found that GM-95 cells, a mutant B16
melanoma cell line that does not express GlcCer synthase (GlcT-
1, UDP-glucose:ceramide glucosyltransferase, EC 2.4.1.80), were
unable to synthesize b-ChlGlc without the addition of exogenous
GlcCer.
GlcCer is degraded in an enzymatic reaction involving the cleav-
age of b-glucosyl linkages between ceramide and glucose by gluco-
cerebrosidase (GCase, GlcCer-degrading glycosidase). Because the
unidentiﬁed SGTase of animal origin transfers the glucose moiety
from GlcCer to cholesterol [8], we examined the possibility that
this SGTase may also be a GCase. To date, four mammalian GCases,
b-glucosidase 1 (GBA1, lysosomal acid GCase, EC 3.2.1.45), b-gluco-
sidase 2 (GBA2, non-lysosomal GCase, EC 3.2.1.45), cytosolic GCase
(GBA3, EC 3.2.1.21), and lactase-phlorizin hydrolase (LPH, EC
3.2.1.62/108) have been identiﬁed. In mammals, catabolism of Glc-
Cer primarily takes places in lysosome by GBA1 [9,10]. Gaucher
disease, caused by an inherited deﬁciency of GBA1, is the most
common lysosomal storage disorder and is characterized by the
accumulation of GlcCer in the lysosomal compartment of macro-
phages [11,12]. GBA1 is speciﬁcally and irreversibly inhibited by
conduritol B epoxide (CBE) [13]. GBA2, which is insensitive to
CBE, is a non-integral membrane-associated protein that localizes
at the cytosolic surface of the ER and Golgi apparatus [14]. GBA2
knockout mice exhibited GlcCer accumulation in the testis, brain,
and liver. The mice showed male infertility [15] and delayed liver
regeneration [16]. GBA3, a cytosolic, Klotho-related protein (KLrP)
whose function is unknown, is insensitive to CBE [17,18]. LPH,
which is sensitive to CBE, is exclusively present in the plasma
membrane of the small intestine and is possibly involved in the
digestion of dietary GlcCer [19]. In the presence of detergent,
GCase activities of GBA1, GBA2, GBA3, and LPH are maximum at
pH 5.0–6.0, pH 5.5–6.5 [14], pH 6.0–7.0 [18], and pH 5.0–6.0
[19], respectively. In the study reported here, we investigated
whether or not these four GCases had SGTase activity. Here we re-
port that, among the four GCases tested, overexpression of GBA1 in
TIG-3 cells led to an increase in SGTase activity in the correspond-
ing cell lysates. We demonstrated that the SGTase activity of puri-
ﬁed recombinant GBA1 is CBE-sensitive. Our studies reveal for the
ﬁrst time that, GBA1 represents a previously unidentiﬁed b-ChlGlc-
synthesizing SGTase. We have characterized the optimum in vitro










(C18:1-GlcCer), and D-glucosyl-ß-1,10 N-nervonoyl-D-erythro-
sphingosine (C24:1-GlcCer) were purchased from Avanti Polar
Lipids (Alabaster, AL, USA). 1-O-cholesteryl-b-D-glucopyranoside
(b-cholesteryl glucoside, b-ChlGlc) was chemically synthesized
according to reported methods [20]. Conduritol-B-epoxide
(D, L-1,2-anhydro-myo-inositol; CBE) was purchased from EnzoLife Sciences (Farmingdale, NY, USA). Cerezyme, a recombinant
human GBA1 used in enzyme replacement therapy in Gaucher
disease [21], was purchased from Genzyme Japan (Tokyo,
Japan).2.2. Cloning of cDNAs encoding GCases
Using speciﬁc primers containing restriction sites and extended
Kozak sequence in front of the start codon, the complete open
reading frames for GBA1 (NM_008094.4), GBA2 (NM_172692.3),
transcript variant 1 of GBA3 (GBA3-tv1, NM_020973.3), transcript
variant 2 of GBA3 (GBA3-tv2, NM_001128432.1), and LPH
(NM_001081078.1) were PCR ampliﬁed frommouse kidney, mouse
testis, GBA3-tv1-pcDNA3.1/Myc-His(+) [18], cDNA clone of
GBA3-tv2 (IMAGE ID; 4612206, GenBank accession number;
BC109377.1), and mouse small intestine, respectively. GBA3-tv1-
pcDNA3.1/Myc-His(+) was generously provided from Dr. Makoto
Ito of Kyusyu University. cDNA clone of GBA3-tv2 was purchased
from Thermo Fisher Scientiﬁc (Waltham, MA, USA). The PCR prod-
uct was subcloned into p3xFLAG-CMV-14 (Sigma–Aldrich, St.
Louis, MO, USA).2.3. Cell culture and transfection
TIG-3 cells were generously provided from Dr. Kazuhiko Kaji of
University of Shizuoka and cultured in Eagle’s minimum essential
medium (MEM; Nissui, Tokyo, Japan) supplemented with 10% fetal
bovine serum (FBS; Biowest, Miami, FL, USA) under 5% CO2 at 37 C.
The population doubling level of TIG-3 cells used in this study was
30.0–40.0. GM00877, a cell line generated from patients with type
2 Gaucher disease, was purchased from Coriel Cell Repositories
(Camden, NJ, USA) and was cultured in Eagle’s minimum essential
medium with Earle’s salts (EEMEM; Sigma–Aldrich) supplemented
with 10% FBS under 5% CO2 at 37 C. Chinese hamster ovary cells
(CHO-K1 cells) (RCB0285, established by Puck, T. T.), were pur-
chased from RIKEN BioResource Center (Ibaraki, Japan) and cul-
tured in Ham’s F-12 medium (Nissui) supplemented with 10%
FBS under 5% CO2 at 37 C. cDNA transfection for TIG-3 and CHO-
K1 cells were carried out using Lipofectamine 2000 Transfection
Reagent (Life Technologies, Carlsbad, CA, USA) according to the
manufacturer’s instructions. After 24 h, medium containing trans-
fection reagents was removed, and cells were harvested after
washing with PBS. For GM00877 cells, cDNA was transfected using
X-tremeGENE HP Transfection Reagent (Roche Applied Science,
Basel, Switzerland) according to the manufacturer’s instructions.
After 48 h, medium containing transfection reagents was removed,
cells were washed with PBS and harvested.2.4. Assay of SGTase activity in vitro
The assay of SGTase activity was carried out according to the
method we established previously [8] with slight modiﬁcations.
The reaction mixture in a total volume of 20 ll contained 40 lM
25-NBD-Cholesterol, 80 lM C16:0-GlcCer, 16 mM citrate–
phosphate buffer, pH 5.0, 0.5% 3-[(3-Cholamidopropyl)dimethyl-
ammonio]propanesulfonate (CHAPS; Dojindo, Kumamoto, Japan),
2% ethanol, and desired amount of enzyme with or without
1 mM ethylenediaminetetraacetic acid (EDTA) and 5 mM
CoCl2. For reactions involving puriﬁed enzyme, the concentration
of citrate–phosphate buffer in the reaction mixture was adjusted
to 50 mM to prevent precipitation during the reaction. After incu-
bation at 37 C for 1 h, the reaction was terminated by adding chlo-
roform/methanol (2:1, v/v), and the lipids were extracted and
analyzed as reported before [8].
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The GCase assay used in this study was carried out according to
the method described by Hayashi et al. [18] with some modiﬁca-
tions. The reaction mixture in a total volume of 20 ll contained
100 pmol C6-NBD-GlcCer, 50 mM citrate–phosphate buffer, pH
5.0, 0.25% Triton X-100, 0.6% sodium taurocholate, and a desired
amount of enzyme. After incubation at 37 C for 30 min, the reac-
tion was terminated by adding chloroform/methanol (2:1, v/v), and
the lipids were extracted. The extracted lipids were separated by
thin layer chromatography on silica gel 60 using chloroform/meth-
anol/water (65:25:4, v/v/v) as eluent. Fluorescence emission of
C6-NBD-ceramide on the silica gel plate was detected using a
LAS-3000 Luminoimaging Analyzer, and was quantiﬁed with Multi
Gauge V2.2 software.2.6. Western blotting
Cells were harvested and lysates were subjected to SDS–PAGE
followed by Western blotting to detect the expression of FLAG
tagged GCases, GBA1, and b-actin. Typically, proteins present in
the cell lysates were separated by SDS–PAGE and transferred to
an Immobilon-P Transfer Membrane (Merck Millipore, Billerica,
MA, USA). Using anti-FLAG M2 (#F1804, Sigma–Aldrich, 1:1,000
dilution) or anti-GBA1 (#G4171, Sigma–Aldrich, 1:10,000 dilution)
or anti-b-actin (#PM053, Medical & Biological Laboratories,
Nagoya, Japan, 1:10,000 dilution) as primary antibodies and horse-
radish peroxidase (HRP)-conjugated anti-rabbit IgG (#170–6515,
Bio-Rad, Hercules, CA, USA, 1:20,000 dilution) or HRP-conjugated
anti-mouse IgG (#55570, Cappel Laboratories, West Chester, PA,
USA, 1:20,000 dilution) as secondary antibodies, immunodetection
was performed using an enhanced chemiluminescence (ECL) sys-
tem (GE Healthcare UK Ltd, Amersham Place, Little Chalfont,
England).2.7. Puriﬁcation of recombinant GBA1
Recombinant mouse GBA1: FLAG tagged mouse GBA1 was
1expressed in CHO-K1 cells and puriﬁed using FLAG immunopre-
cipitation kit (Sigma–Aldrich) according to the manufacturer’s
instructions. The expression of GBA1 was tested using immunopre-
cipitated samples by Western blotting as described earlier.Fig. 1. SGTase activities in the lysates of TIG-3 cells transfected with cDNA encoding GCa
GBA3-tv1, GBA3-tv2, LPH, andmock represent the transfectants with cDNA encoding the re
ANOVA with Dunnett’s post hoc test, n = 4. ⁄⁄P < 0.01 compared with SGTase activity of m
tagged GCase and b-actin were determined using anti-FLAG M2 or anti-b-actin as primaRecombinant human GBA1: Cerezyme, was dialyzed and degly-
cosylated according to reported methods [22]. Typically, 5 ng pro-
tein (0.5 lU) was used for each assay. One unit of b-glucosidase
activity was deﬁned as the amount of enzyme required to release
1 lmol of p-nitrophenol from p-nitrophenyl-b-D-glucopyranoside
per minute at pH 5.0 and 37 C.2.8. Statistical analysis
Statistical analyses were performed using GraphPad Prism ver-
sion 5.0 for Windows (GraphPad Software, San Diego, CA, USA).
Mean ± SEM values were calculated for all values. The data were
analyzed using one-way analysis of variance (ANOVA) with
Dunnett’s post hoc-test or unpaired Student’s t-test. A P value
<0.05 was considered as statistically signiﬁcant.3. Results
3.1. GBA1 is a candidate for mammalian SGTase
To identify animal SGTase, we attempted to examine SGTase
activity of four known GCases (GBA1, GBA2, GBA3, and LPH) over-
expressed in TIG-3 cells. Two transcript variants of GBA3 (GBA3-
tv1 and GBA3-tv2) differing in their lengths were examined. Our
results showed that SGTase activity increased signiﬁcantly in ly-
sates of TIG-3 cells overexpressing GBA1 (Fig. 1). Almost the same
results were obtained at the reaction condition between pH 5.0 and
6.2 (data not shown).
To verify whether GBA1 had SGTase activity, we used the
GM00877 cell line generated from patients with type 2 Gaucher
disease. Protein levels of GBA1, GCase activity, and SGTase activity
in the lysates of GM00877 cells transfected with empty vector
were lower than in those of TIG-3 cells (Fig. 2). Interestingly, over-
expression of GBA1 in GM00877 cells resulted in an increase in the
protein level of GBA1, leading to elevated GCase and SGTase activ-
ities. Two other cell lines, GM00372 and GM00852, generated from
patients with type 1 Gaucher disease (Coriel Cell Repositories), also
showed low expression level of GBA1 protein, as well as low GCase
and SGTase activities compared to TIG-3 cells (Fig. S1). However,
low transfection efﬁciency prevented us from conﬁrming the effect
of GBA1 overexpression in GM00372 and GM00852 cells.se. (A) SGTase activity of cell lysates prepared from TIG-3 transfectants. GBA1, GBA2,
spective GCase or empty vector (mock). Differences were established using one-way
ock. (B) Western blotting of GCase expressed in TIG-3 cells. Protein levels of FLAG
ry antibodies.
Fig. 2. SGTase activities in the lysates of GM00877 cells transfected with cDNA encoding GBA1. (A) SGTase activity in the lysates of GM00877 transfectants and TIG-3 cells.
GBA1 and mock represent the cells transfected with cDNA encoding GBA1 or empty vector (mock). (B) GCase activity in the lysates of GM00877 transfectants and TIG-3 cells.
Differences were established using unpaired Student’s t-test, n = 4. ⁄P < 0.05; ⁄⁄P < 0.01; ⁄⁄⁄P < 0.001; ⁄⁄⁄⁄P < 0.0001. (C) Western blotting of GBA1 expressed in GM00877
transfectants and TIG-3 cells. Protein levels of FLAG tagged GCase, GBA1, and b-actin were determined using anti-FLAG M2, anti-GBA1, and anti-b-actin, respectively, as
primary antibodies.
Fig. 3. SGTase and GCase activities of puriﬁed recombinant GBA1. (A and D) SGTase activity of puriﬁed recombinant GBA1 frommouse (A) and human (D). The SGTase activity
was measured with or without 0.5 mM CBE. (B and E) GCase activity of puriﬁed recombinant GBA1 from mouse (B) and human (E). The activity of GCase was measured with
or without 0.5 mM CBE. In (A) and (B), GBA1 and mock represent the puriﬁed proteins from CHO-K1 transfectants with cDNA encoding mouse GBA1 or empty vector (mock).
Differences were established using unpaired Student’s t-test, n = 4. ⁄⁄⁄P < 0.001; ##P < 0.005; ⁄⁄⁄⁄P < 0.0001. (C) Western blot analysis of GBA1 puriﬁed from CHO-K1
transfectants. Protein levels of GBA1 in the cell lysates of CHO-K1 transfectants (Input) and in the puriﬁed products (IP:FLAG) were determined using anti-GBA1 or anti-b-actin
as primary antibodies.
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To verify whether GBA1 catalyzes cholesterol glucosylation, we
puriﬁed recombinant human and mouse GBA1 as described under
the ‘‘Materials and methods’’ section. Results of our in vitro assays
using puriﬁed proteins showed that recombinant mouse GBA1 had
GCase and SGTase activities, which were sensitive to CBE. Further,
we found that these activities were not observed in products puri-
ﬁed from CHO-K1 cells transfected with empty vector (Fig. 3A–C).
Additionally, we found that deglycosylated-Cerezyme, when used
as the puriﬁed recombinant human counterpart of mouse GBA1,exhibited CBE-sensitive GCase and SGTase activities (Fig. 3D and
E). These results demonstrate that GBA1 acts as a b-ChlGlc-synthe-
sizing enzyme. We also found that NBD-ChlGlc formed during the
in vitro reactions had glycosidic bonds in the b-conﬁguration
(Fig. S2).
3.3. Characterization of optimum conditions for the synthesis of
b-ChlGlc by human GBA1 in vitro
Using deglycosylated-Cerezyme, we determined the optimum
conditions required for SGTase activity of human GBA1 in vitro.
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continuously up to 24 h examined (Fig. 4A). Using enzymatically
synthesized NBD-ChlGlc [8] as a substrate, we conﬁrmed that hu-
man GBA1 has b-ChlGlc-degrading activity (Fig. S2). We observed
that the SGTase activity of human GBA1 was maximum at about
pH 5.3 (Fig. 4B) and 43 C (Fig. 4C). Divalent cations (Mg2+, Ca2+,
Mn2+, Co2+, Ni2+, Cu2+, Zn2+, and Ba2+) at 1–10 mM concentrations
had no effect on increase of the SGTase activity (data not shown).
As shown in Fig. 4D, among the GlcCer containing saturated fatty
acids (C8:0 to C18:0) tested, short chain C8:0-GlcCer was found
to be most effective glucose donor for SGTase. We also found that
C18:1-GlcCer was more suitable as a SGTase substrate than C18:0-
GlcCer. Therefore, GlcCer containing mono-unsaturated fatty acid
is considered to be more preferred substrate for cholesterol glu-
cosylation when compared with GlcCer containing same chain
length of saturated fatty acid.4. Discussion
SGTases in a number of organisms are known to use UDP-glu-
cose as the glucose donor and have been identiﬁed and cloned
[1]. However, the identity of the animal counterparts of these
SGTases remained elusive. The results presented here demonstrate
that, in human and mouse, GBA1 is responsible for the synthesis of
b-ChlGlc from GlcCer and cholesterol. Therefore, we suggest that
GBA1 represents a previously unidentiﬁed mammalian SGTase.
As shown in Fig. 3, CBE inhibited the SGTase activity of GBA1
in vitro. The crystal structure of GBA1 with bound CBE revealed
that CBE binds to the active site of GCase [23]. Therefore, weFig. 4. Characterization of optimum conditions for b-ChlGlc synthesis by puriﬁed human
(n = 4–6). (B) pH dependence of SGTase activity of human GBA1. The activity of SGTase w
in the inset of B (n = 3). (C) Temperature dependence of SGTase activity of human GBA1. Th
pH 5.3 (n = 4–6). SGTase activity at 37 C was arbitrarily set as 100%. (D) Substrate speciﬁ
at 37 C for 1 h at pH 5.3 using various GlcCer (C8:0-GlcCer, C12:0-GlcCer, C16:0-GlcCer
activity of SGTase measured using C16:0-GlcCer was arbitrarily set as 100%.hypothesized that the inhibitory effect CBE on b-ChlGlc formation
may have been caused by reduced GlcCer degradation followed by
a decrease in the amount of transposable glucose.
Previously, GBA1 has been found to catalyze not only GlcCer
hydrolysis but also transglucosylation reactions. Formation of
b-ChlGlc catalyzed by GBA1 is considered to be a transglucosyla-
tion reaction between GlcCer and cholesterol. Partially puriﬁed
GBA1 from the calf brain has been found to catalyze transglucosy-
lation reactions between an artiﬁcial glucose donor, 4-methylum-
belliferone b-D-glucoside and ceramide [24]. Additionally, it was
reported that human placental GBA1 catalyzes the reaction be-
tween GlcCer and two alcohols, namely n-pentanol and retinol
[25], but the products of the reaction, N-pentyl glucoside and ret-
inyl glucoside are not naturally occurring substances. Compared
to these reactions, b-ChlGlc formation we demonstrated here is no-
vel GBA1-mediated transglucosylation reaction because the mole-
cules involved in b-ChlGlc formation are naturally occurring ones.
The relationship between GBA1 mutations and transglucosylation
activity has been reported. Thus, N370S mutation, a common
GBA1 mutation in non-neuropathic Gaucher disease (type 1)
patients, altered the activity of both hydrolysis and transglucosyla-
tion [26]. Since it is not known as to whether or not GBA1 catalyzes
transglucosylation reactions in vivo, further studies are needed to
elucidate the mechanisms responsible for the biosynthesis of
b-ChlGlc in organisms.
Using the puriﬁed recombinant human GBA1, we characterized
the optimumconditions for SGTase activity in vitro (Fig. 4). The opti-
mum pH and temperature requirements for maximal SGTase activ-
ity of GBA1 were similar to those reported for its GCase activity
[14,27,28]. It has been reported that, among GlcCer containingGBA1 in vitro. (A) Time course of b-ChlGlc synthesis by human GBA1 at 37 C, pH 5.0
as measured at 37 C for 1 h in a 50 mM concentration of the various buffers shown
e activity of SGTase was measured within a temperature range of 27–60 C for 1 h at
city of SGTase activity present in human GBA1. The activity of SGTase was measured
, C18:0-GlcCer, C18:1-GlcCer, and C24:1-GlcCer) as the glucose donor (n = 5–6). The
H. Akiyama et al. / Biochemical and Biophysical Research Communications 441 (2013) 838–843 843saturated fatty acids (C1:0 to C18:0), GCase activity of GBA1 showed
substrate preference toward C8:0-GlcCer [29]. In our experiments,
we found that among the GlcCer containing saturated fatty acids
(C8:0 to C18:0) tested, C8:0-GlcCer was the most effective glucose
donor for SGTase. For GCase activity of GBA1, substrate speciﬁcity
among GlcCer containing unsaturated fatty acid has not been stud-
ied and reported. Here, we demonstrated that GlcCer containing
mono-unsaturated fatty acid was more preferred substrate for cho-
lesterol glucosylationwhen comparedwith GlcCer containing same
chain length of saturated fatty acid. It is possible that transfer glu-
cose fromceramide to cholesterol becomeseasier in thebent confor-
mation, cis-double bond, of the unsaturated fatty acid.
We have reported that SGTase activity is present in the lipid raft
fraction of TIG-3 cells [30]. Because GBA1 is a lysosomal enzyme,
we suggested that b-ChlGlc is probably synthesized in lipid rafts
present in the lysosomes. Although the physiological signiﬁcance
of cholesterol glucosylation in animals is not known, glucosylation
alters the physical properties of cholesterol, due to the reduction of
the depth of sterol moiety embedded in the bilayer caused by the
large polar head group [31]. A comparison of models of artiﬁcial
liposomes before and after the formation of b-ChlGlc suggested
that, transfer of glucose moiety from GlcCer to cholesterol results
in a change in membrane physical properties, forming thermosta-
ble solid-ordered domains [30]. Therefore, it is likely that b-ChlGlc
may be involved in modulating the physical properties of lyso-
somal membrane. Further studies are necessary to understand
the function of b-ChlGlc in lysosomes. Our identiﬁcation of GBA1
as the mammalian enzyme responsible for b-ChlGlc formation is
a key step towards understanding the in vivo roles of b-ChlGlc in
mammals.
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